WESTON | Jotup

ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

Retrieved on:

Tuesday, September 12, 2023

Inflammation, ASC, Frontiers, Spinal cord, NLRP3, CNS, Inflammasome, Therapy, ALS, Pharmaceutical industry, Vaccine, Immunology

This paper supports ZyVersa’s rationale for targeting inflammasome ASC with IC 100 to inhibit multiple inflammasome pathways, not just NLRP3, to control inflammation in various inflammatory diseases.

Key Points:

This paper supports ZyVersa’s rationale for targeting inflammasome ASC with IC 100 to inhibit multiple inflammasome pathways, not just NLRP3, to control inflammation in various inflammatory diseases.
Data demonstrate that NLRP3 inhibition alone is insufficient to attenuate proinflammatory cytokine release and inflammatory cell death associated with activation of multiple inflammasome pathways.
Likewise, NLRP3 inhibition alone did not ameliorate spinal cord inflammation in an ALS model.
“The research published in Frontiers in Immunology reinforces the need to inhibit more than the NLRP3 inflammasome pathway to control inflammation associated with activation of multiple inflammasomes,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President.

ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results

Retrieved on:

Monday, August 21, 2023

WESTON, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq-GM: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today provides a corporate update and reports financial results for the second quarter of 2023 ending June 30, 2023.

Key Points:

“The second quarter of 2023 was a period of continued progress at ZyVersa as we completed key corporate, developmental, regulatory and financial initiatives designed to position the company to achieve value-building milestones involving our Cholesterol Efflux Mediator™ VAR 200 and Inflammasome ASC Inhibitor IC 100,” said Stephen C. Glover, Co-founder, Chairman, Chief Executive Officer, and President of ZyVersa.
“We are pleased to report our VAR 200 program is progressing as planned, and we anticipate initiation of a Phase 2a clinical trial in diabetic kidney disease (DKD) in the first quarter of 2024.
The increase is primarily attributable to an increase of $0.5 million in the costs of manufacturing of IC 100.
The impairment is a result of the decline in ZyVersa’s market capitalization as of June 30, 2023.

ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering

Retrieved on:

Monday, July 24, 2023

Telephone, SEC filing, Sale, Prospectus, Form, Madison Avenue, Security (finance), Therapy

The warrants will have an exercise price of $0.165 per share, will be exercisable immediately, and will expire five years from the initial issuance date.

Key Points:

The warrants will have an exercise price of $0.165 per share, will be exercisable immediately, and will expire five years from the initial issuance date.
The closing of the offering is expected to occur on or about July 26, 2023, subject to the satisfaction of customary closing conditions.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The offering is being made only by means of a prospectus forming part of the effective registration statement.

ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis

Retrieved on:

Monday, July 17, 2023

ASC, Hepatic stellate cell, NLRP3, Inflammation, Inflammasome, Health, Super Meat Boy, Patient, Mouse, Therapy, Cirrhosis, Clothing, Pharmaceutical industry, Medical imaging, Hepatology

In the paper titled, “Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis,” the authors evaluated serum levels of IL-18 in patients diagnosed with liver fibrosis/cirrhosis, and they conducted studies in three different mouse models of liver fibrosis.

Key Points:

In the paper titled, “Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis,” the authors evaluated serum levels of IL-18 in patients diagnosed with liver fibrosis/cirrhosis, and they conducted studies in three different mouse models of liver fibrosis.
Following are key findings reported in the paper:
The pivotal role of IL-18 signaling in liver fibrosis was confirmed in IL-18 deficient mice, which showed protection from fibrotic liver changes
The authors stated, “Our results highlight the pivotal role of IL-18 signaling in liver fibrogenesis through the activation of HSCs in vitro and in vivo in three different mouse models.” To read the article, Click Here .
“The research published in the Hepatology demonstrated that NLRP3 inflammasome-mediated activation of IL-18 has a pivotal role in liver fibrosis, providing support for inflammasome inhibition as a promising treatment.
To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here .

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023

Retrieved on:

Friday, July 14, 2023

Chronic kidney disease, CNS, Dialysis, CDC, VAR, Kidney, Entrepreneurship, Therapy, Conference, Kidney disease, Inflammation, Pharmaceutical industry

During the presentation, Mr. Glover will highlight the unique mechanism of action of Cholesterol Efflux Mediator™ VAR 200 and its potential role in the treatment of kidney disease.

Key Points:

During the presentation, Mr. Glover will highlight the unique mechanism of action of Cholesterol Efflux Mediator™ VAR 200 and its potential role in the treatment of kidney disease.
“We are pleased to have the opportunity to discuss the unique mechanism of action of Cholesterol Efflux Mediator™ VAR 200 and its potential role in the treatment of kidney disease at the H.C. Wainwright 2nd Annual Kidney Conference,” stated Mr. Glover.
“Around 36 million people in the US have chronic kidney disease which progresses over time leading to the need for dialysis and kidney transplant, yet treatment options are limited.
According to the CDC, in 2020 nearly 558,000 people were on dialysis and nearly 250,000 were living with a kidney transplant.

ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress

Retrieved on:

Monday, July 10, 2023

Heart, ASC, Central nervous system, Heart failure, Inflammasome, Stroke, Sens, ATP, NLRP3, Research, Cardiomegaly, Fibroblast, Inflammation, Vivo, Risk, Therapy, Arrhythmia, Pharmaceutical industry, Hypertrophy

The objective was to determine the regulatory mechanism of inflammation and its role in the stressed heart.

Key Points:

The objective was to determine the regulatory mechanism of inflammation and its role in the stressed heart.
Hypertrophic heart disease puts people at greater risk of heart failure, stroke, and cardiac arrhythmias, including sudden cardiac death.
Likewise, IC 100 uniquely inhibits ASC specks to block perpetuation of damaging inflammation,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President.
To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here .

European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

Retrieved on:

Friday, July 7, 2023

Patent, University, Cholesterol, European Patent Office, Lipid, Research, Alport syndrome, Nephrology, Alport, VAR, Patient, Focal segmental glomerulosclerosis, Invention, European Patent Convention, Diabetic nephropathy, Therapy, Pharmaceutical industry, Medicine

VAR 200 was developed in the labs of Dr. Alessia Fornoni, Katz Professor of Medicine, Chief, Katz Family Division of Nephrology & Hypertension, and Director of Peggy & Harold Katz Drug Discovery Center at the University of Miami.

Key Points:

VAR 200 was developed in the labs of Dr. Alessia Fornoni, Katz Professor of Medicine, Chief, Katz Family Division of Nephrology & Hypertension, and Director of Peggy & Harold Katz Drug Discovery Center at the University of Miami.
“Approval of this patent claiming our Cholesterol Efflux Mediator™ VAR 200 for use in treating diabetic kidney disease speaks to the innovative and important research conducted by Dr. Fornoni and her team involving removal of excess cholesterol and lipids that damage the kidneys’ filtration system.
There are no therapeutic options available that address this issue,” said Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO, and President.
There is a tremendous need for effective treatments to slow progression of renal disease.”

ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity

Retrieved on:

Wednesday, June 28, 2023

ASC, Inflammasome, Urine, NLRP3, Journal of Clinical Immunology, Inflammation, Kidney, LN, Proteinuria, Super Meat Boy, Journal, Patient, Lupus nephritis, Therapy, Biopsy, Disease, Pharmaceutical industry, Medical imaging

In the paper titled, “Renal NLRP3 Inflammasome activation is associated with disease activity in lupus nephritis,” the authors evaluated renal biopsy tissue of patients with biopsy proven LN in comparison to control tissue.

Key Points:

In the paper titled, “Renal NLRP3 Inflammasome activation is associated with disease activity in lupus nephritis,” the authors evaluated renal biopsy tissue of patients with biopsy proven LN in comparison to control tissue.
Data demonstrated that renal NLRP3 inflammasome activation positively correlated with LN severity and clinicopathological indices of LN.
NLRP3 was extensively activated in various renal intrinsic cells and infiltrating cells, and was closely associated with disease activity, which needs further explorations.” To read the article, Click Here .
“The research published in the Journal of Clinical Immunology demonstrated that renal NLRP3 inflammasome activation is associated with lupus nephritis disease activity, providing support for inflammasome inhibition as a promising treatment for LN.

Canada Bread Resolves Competition Bureau Inquiry into Packaged Bread

Retrieved on:

Wednesday, June 21, 2023

Ontario Superior Court of Justice, Maple Leaf Foods, Competition, Loblaws, Grupo Bimbo, Sale, Investment, Competition Bureau, Maple syrup, Medical device, Canada Bread, Limited

TORONTO, June 21, 2023 /CNW/ - In a proceeding in the Ontario Superior Court in Toronto today, Canada Bread Company, Limited ("Canada Bread") resolved allegations made against it as part of an investigation by the Competition Bureau of Canada ("Competition Bureau") into packaged bread that began in 2016.

Key Points:

TORONTO, June 21, 2023 /CNW/ - In a proceeding in the Ontario Superior Court in Toronto today, Canada Bread Company, Limited ("Canada Bread") resolved allegations made against it as part of an investigation by the Competition Bureau of Canada ("Competition Bureau") into packaged bread that began in 2016.
Canada Bread will pay a $50 million fine concerning two wholesale price increases implemented by Weston Foods (Canada) Inc. ("Weston") and Canada Bread more than a decade ago, when Canada Bread was majority owned and controlled by Maple Leaf Foods Inc. (Maple Leaf Foods).
Under Grupo Bimbo's ownership, Canada Bread provided material and consistent cooperation to the Competition Bureau.
We are pleased to have resolved this matter, and we look forward to building upon our investments in Canada" said Alice Lee, Vice President, Canada Bread.

ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)

Retrieved on:

Tuesday, June 20, 2023

ZyVersa’s Inflammasome ASC Inhibitor IC 100 inhibits the inflammasome adaptor protein ASC, a component of multiple types of inflammasomes including NLRP3 inflammasomes.

Key Points:

ZyVersa’s Inflammasome ASC Inhibitor IC 100 inhibits the inflammasome adaptor protein ASC, a component of multiple types of inflammasomes including NLRP3 inflammasomes.
In the paper titled, “NLRP3 Inflammasome Activation in Peripheral Arterial Disease,” the authors evaluated human peripheral arteries from patients undergoing limb amputation and serum collected prior to surgery.
Data demonstrated an association between NLRP3, macrophage accumulation, and calcification in arteries of patients with PAD, suggesting that NLRP3 inflammasome activation may be a driver of the disease.
Inhibition of the NLRP3 inflammasome activation or downstream signaling cascade may be beneficial to the reduction of inflammatory-driven PAD.” To read the article, Click Here .